MARKET

CHMA

CHMA

Chiasma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.790
+0.080
+1.70%
After Hours: 4.560 -0.23 -4.80% 19:50 08/07 EDT
OPEN
4.730
PREV CLOSE
4.710
HIGH
4.830
LOW
4.600
VOLUME
320.60K
TURNOVER
--
52 WEEK HIGH
7.75
52 WEEK LOW
2.880
MARKET CAP
262.33M
P/E (TTM)
-4.3605
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CHMA stock price target is 15.20 with a high estimate of 19.00 and a low estimate of 11.00.

EPS

CHMA News

More
Chiasma to Report Second Quarter 2020 Results on August 10
Company to host conference call and webcast at 5:00 p.m. ETNEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast
GlobeNewswire · 5d ago
Chiasma's octreotide shows sustained benefit in acromegaly extension study
Seeking Alpha · 07/27 20:31
UPDATE: Chiasma Says Mean Of IGF-1 Levels For Population Of All MYCAPSSA-Treated Patients That Completed 36-Week Core CHIASMA OPTIMAL Trial And Continued Into OLE 'was maintained within normal limits at the end of the 48-week OLE period'
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within
The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within · 07/27 20:04
UPDATE: Chiasma Says 'All MYCAPSSA responders (IGF-1 within normal limits) who enrolled into the OLE completed the 48-week period; 93% maintained their response at the end of this period;
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within
The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within · 07/27 20:03
Chiasma Announces 48-Week Safety And Efficacy Data From Open-Label Extension Study Of CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within
The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within · 07/27 20:03
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly
\-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within normal limits at the end of the 48-week OL
GlobeNewswire · 07/27 20:01
64 Biggest Movers From Yesterday
Gainers InnerWorkings, Inc. (NASDAQ: INWK) shares jumped 115.9% to close at $2.85 on Thursday after HH Global announced plans to acquire the company for $3 per share.
Benzinga · 07/17 09:08
Were Hedge Funds Right About Chiasma Inc (CHMA)?
Insider Monkey · 07/09 02:21

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CHMA

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.
More

Webull offers kinds of Chiasma Inc stock information, including NASDAQ:CHMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHMA stock methods without spending real money on the virtual paper trading platform.